雷帕霉素调控巨噬细胞表型改善肺动脉高压
Rapamycin improved pulmonary artery hypertension via modulating the phenotypes of macrophages

DOI: 10.6040/j.issn.1671-7554.0.2017.850

Keywords: 肺动脉高压,肺动脉平滑肌细胞,白介素-1β,雷帕霉素,巨噬细胞,表型转换,白介素-6,
Pulmonary arterial hypertension,Macrophages,Interleukin-lβ,Pulmonary arterial smooth muscle cells,Phenotype transformation,Interleukin-6,Rapamycin

Full-Text   Cite this paper   Add to My Lib

Abstract:

References

[1]	Pereira SL, Kummerle AE, Fraga CA, et al. A novel Ca<sup>2+</sup> channel antagonist reverses cardiac hypertrophy and pulmonary arteriolar remodeling in experimental pulmonary hypertension[J]. Eur J Pharmacol, 2013, 702(1-3): 316-322.
[2]	Alencar AK, Pereira SL, Montagnoli TL, et al. Beneficial effects of a novel agonist of the adenosine A2A receptor on monocrotaline-induced pulmonary hypertension in rats[J]. Br J Pharmacol, 2013, 169(5): 953-962.
[3]	Vaillancourt M, Ruffenach G, Meloche J, et al. Adaptation and remodelling of the pulmonary circulation in pulmonary hypertension[J]. Can J Cardiol, 2015, 31(4): 407-415.
[4]	Kiss T, Kovacs K, Komocsi A, et al. Novel mechanisms of sildenafil in pulmonary hypertension involving cytokines/chemokines, MAP kinases and Akt[J]. PLoS One, 2014, 9(8): e104890. doi: 10.1371/journal.pone.0104890.
[5]	Chen T, Yang C, Li M, et al. Alveolar hypoxia-induced pulmonary inflammation: from local initiation to secondary promotion by activated systemic inflammation[J]. J Vasc Res, 2016, 53(5-6): 317-329.
[6]	Yeager ME, Reddy MB, Nguyen CM, et al. Activation of the unfolded protein response is associated with pulmonary hypertension[J]. Pulm Circ, 2012, 2(2): 229-240.
[7]	郑亚国.肺动脉高压免疫炎症机制研究进展[J].中国循环杂志, 2013, 28(6): 469-471.
[8]	Antunes MA, Abreu SC, Cruz FF, et al. Effects of different mesenchymal stromal cell sources and delivery routes in experimental emphysema[J]. Respir Res, 2014, 15: 118.
[9]	余莉,范志宇,谢亮,等.雷帕霉素逆转大鼠肺动脉高压的作用机制研究[J].中国当代儿科杂志,2015, 17(7):731-735. YU Li, FAN Zhiyu, XIE Liang, et al. Mechanisms for reversal of pulmonary hypertension by rapamycin in rats[J]. Chin J Contemp Pediatr, 2015, 17(7):731-735.
[10]	Kishimoto Y, Kato T, Ito M, et al. Hydrogen ameliorates pulmonary hypertension in rats by anti-inflammatory and antioxidant effects[J]. J Thorac Cardiovasc Surg, 2015, 150(3): 645-654.
[11]	Vergadi E, Chang MS, Lee C, et al. Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension[J]. Circulation, 2011, 123(18): 1986-1995.
[12]	Martinez FO, Sica A, Mantovani A, et al. Macrophage activation and polarization[J]. Front Biosci, 2008, 13: 453-461.
[13]	Vats D, Mukundan L, Odegaard JI, et al. Oxidative metabolism and PGC-1β attenuate macrophage-mediated inflammation[J]. Cell metabolism, 2006, 4(1): 13-24.
[14]	Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension[J]. Chest, 2012, 141(1): 210-221.
[15]	Segura-Ibarra V, Amione-Guerra J, Cruz-Solbes AS, et al. Rapamycin nanoparticles localize in diseased lung vasculature and prevent pulmonary arterial hypertension[J]. Int J Pharm, 2017, 524(1-2): 257-267.
[16]	Wang AP, Li XH, Yang YM, et al. A critical role of the mTOR/eIF2α pathway in hypoxia-induced pulmonary hypertension[J]. PLoS One, 2015, 10(6): e0130806. doi: 10.1371/journal.pone.0130806.
[17]	Zhu L, Yang T, Li L, et al. TSC1 controls macrophage polarization to prevent inflammatory disease[J]. Nat Commun, 2014, 5: 4696.
[18]	刘斌,王献民,魏丽,等. 4种肺动脉高压动物模型肺血管重构模式的差异研究[J].中国病理生理杂志, 2008, 24(2): 289-293. LIU Bin, WANG Xianmin, WEI Li, et al. Differentiation of pulmonary vascular remodeling pattern in 4 models of pulmonary hypertension[J]. Chinese Journal of Pathophysiology, 2008, 24(2): 289-293.
[19]	Hansson GK. Atherosclerosis-an immune disease: the Anitschkov Lecture 2007[J]. Atherosclerosis, 2009, 202(1): 2-10.
[20]	Perros F, Dorfmüller P, Montani D, et al. Pulmonary lymphoid neogenesis in idiopathic pulmonary arterial hypertension[J]. Am J Respir Crit Care Med, 2012, 185(3): 311-321.
[21]	Sutendra G, Dromparis P, Bonnet S, et al. Pyruvate dehydrogenase inhibition by the inflammatory cytokine TNFα contributes to the pathogenesis of pulmonary arterial hypertension[J]. J Mol Med(Berl), 2011, 89(8): 771-783.
[22]	Ogawa A, Nakamura K, Matsubara H, et al. Prednisolone inhibits proliferation of cultured pulmonary artery smooth muscle cells of patients with idiopathic pulmonary arterial hypertension[J]. Circulation, 2005, 112(12): 1806-1812.
[23]	Aghamohammadzadeh R, Zhang YY, Stephens TE, et al. Up-regulation of the mammalian target of rapamycin complex 1 subunit Raptor by aldosterone induces abnormal pulmonary artery smooth muscle cell survival patterns to promote pulmonary arterial hypertension[J]. FASEB J, 2016, 30(7): 2511-2527.
[24]	Tian W, Jiang X, Tamosiuniene R, et al. Blocking macrophage leukotriene b4 prevents endothelial injury and reverses pulmonary hypertension[J]. Sci Transl Med, 2013, 5(200): 200ra117.
[25]	Price LC, Montani D, Tcherakian C, et al. Dexamethasone reverses monocrotaline-induced pulmonary arterial hypertension in rats[J]. Eur Respir J, 2011, 37(4): 813-822.
[26]	Ma X, Yao J, Yue Y, et al. Rapamycin reduced pulmonary vascular remodelling by inhibiting cell proliferation via Akt/mTOR signalling pathway down-regulation in the carotid artery-jugular vein shunt pulmonary hypertension rat model[J]. Interact Cardiovasc Thorac Surg, 2017, 25(2): 206-211.
[27]	Desai A, Desouza SA. Treatment of pulmonary hypertension with left heart disease: a concise review[J]. Vasc Health Risk Manag, 2017, 13: 415-420.
[28]	Vergadi E, Chang MS, Lee C, et al. Early macrophage recruitment and alternative activation are critical for the later development of hypoxia-induced pulmonary hypertension[J]. Circulation, 2011, 123(18): 1986-1995.

Full-Text